Harry C. Dietz

Harry C. Dietz

Auto-generated profile, based on publicly available information

Harry C. Dietz

McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2006 in Science
Verified
Journal Article
Closed access
PDF file
JHJennifer P. Habashi
Jennifer P. Habashi
DJDaniel Judge
Daniel Judge
THTammy M. Holm
Tammy M. Holm
RCRonald D. Cohn
Ronald D. Cohn
BLBart Loeys
Bart Loeys
HDHarry C. Dietz
Harry C. Dietz
Aortic aneurysm and dissection are manifestations of Marfan syndrome (MFS), a disorder caused by mutations in the gene that encodes fibrillin-1. Selected manifestations of MFS reflect excessive signaling by the transforming growth factor–β (TGF-β) family of cytokines. We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-β signaling and can be prevented by TGF-β antagonists such as TGF-β–neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation. These data suggest that losartan, a drug already in clinical use for hypertension, merits investigation as a therapeutic strategy for patients with MFS and has the potential to prevent the major life-threatening manifestation of this disorder.

1 December 2005 in The Lancet
Verified
Journal Article
Closed access
DJDaniel Judge
Daniel Judge
HDHarry C Dietz
Harry C Dietz

26 June 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
BBBenjamin S. Brooke
Benjamin S. Brooke
JHJennifer P. Habashi
Jennifer P. Habashi
DJDaniel Judge
Daniel Judge
NPNishant Patel
Nishant Patel
BLBart Loeys
Bart Loeys
HDHarry C. Iii Dietz
Harry C. Iii Dietz
Progressive enlargement of the aortic root, leading to dissection, is the main cause of premature death in patients with Marfan's syndrome. Recent data from mouse models of Marfan's syndrome suggest that aortic-root enlargement is caused by excessive signaling by transforming growth factor β (TGF-β) that can be mitigated by treatment with TGF-β antagonists, including angiotensin II–receptor blockers (ARBs). We evaluated the clinical response to ARBs in pediatric patients with Marfan's syndrome who had severe aortic-root enlargement. We identified 18 pediatric patients with Marfan's syndrome who had been followed during 12 to 47 months of therapy with ARBs after other medical therapy had failed to prevent progressive aortic-root enlargement. The ARB was losartan in 17 patients and irbesartan in 1 patient. We evaluated the efficacy of ARB therapy by comparing the rates of change in aortic-root diameter before and after the initiation of treatment with ARBs. The mean (±SD) rate of change in aortic-root diameter decreased significantly from 3.54±2.87 mm per year during previous medical therapy to 0.46±0.62 mm per year during ARB therapy (P<0.001). The deviation of aortic-root enlargement from normal, as expressed by the rate of change in z scores, was reduced by a mean difference of 1.47 z scores per year (95% confidence interval, 0.70 to 2.24; P<0.001) after the initiation of ARB therapy. The sinotubular junction, which is prone to dilation in Marfan's syndrome as well, also showed a reduced rate of change in diameter during ARB therapy (P<0.05), whereas the distal ascending aorta, which does not normally become dilated in Marfan's syndrome, was not affected by ARB therapy. In a small cohort study, the use of ARB therapy in patients with Marfan's syndrome significantly slowed the rate of progressive aortic-root dilation. These findings require confirmation in a randomized trial.

21 January 2007 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RCRonald D Cohn
Ronald D Cohn
CEChristel van Erp
Christel van Erp
JHJennifer P Habashi
Jennifer P Habashi
ASArshia A Soleimani
Arshia A Soleimani
EKErin C Klein
Erin C Klein
HDHarry C Dietz
Harry C Dietz

18 May 2011 in Nature
Verified
Journal Article
Closed access
PDF file
MLMark E. Lindsay
Mark E. Lindsay
HDHarry C. Dietz
Harry C. Dietz

15 April 2011 in Science
Verified
Journal Article
Closed access
PDF file
THTammy M. Holm
Tammy M. Holm
JHJennifer P. Habashi
Jennifer P. Habashi
JDJefferson J. Doyle
Jefferson J. Doyle
DBDjahida Bedja
Djahida Bedja
YCYiChun Chen
YiChun Chen
HDHarry C. Dietz
Harry C. Dietz
Transforming growth factor–β promotes aortic aneurysm formation through activation of its “noncanonical” signaling pathway.